Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
Details : Under the licence agreement, Bristol Myers Squibb has selected an undisclosed number of programmes that were rapidly developed and progressed using Evotec's precision medicine platforms for further development within the expanded collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
November 07, 2023
Details : Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
March 27, 2023
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
Details : EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications. The EVT8683 programme originates from a phenotypic screen conducted by Evotec using its IPSC drug discovery platform.
Product Name : EVT8683
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 16, 2022
Centogene Announces Expansion of Data Access and Collaboration Agreement With Pfizer
Details : The initial agreement, which granted Pfizer access to data of interest from CENTOGENE’s Bio/Databank, was established in 2019 to advance the discovery and validation of novel genetic targets as candidates for the development of new therapies for rare d...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 17, 2022
Details : The collaboration will incorporate DZNE’s expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 17, 2021